Growth failure
Gene: IRS1
ESHG 2026
9 individuals from 4 Turkish families with homozygous variants in the IRS1 gene (p.F222del, p.His598Alafs*13). Segregation data not presented. All individuals presented with severe pre/postnatal growth failure (HT/WT/OFC <-3SD), severe insulin resistance, lipoatrophy, osteopenia, developmental delay, intellectual disability, and triangular facies with bulbous nose. Biochemical analysis showed low leptin levels, elevated adiponectin, mildly increased IGFBP3, low/normal cholesterol.
IRS1 is a key adaptor in insulin and IGF-1 signalling pathways. Patient-derived fibroblast demonstrated preserved IRS1 expression and intracellular localization for the variants, but impaired IRS1-mediated signalling, characterized by reduced ERK phosphorylation and increased FOXO1 expression. Variant-specific IRS1 mouse models exhibited severe growth restriction, insulin resistance, reduced adipocyte volume, and reduced bone strength.Created: 18 Aug 2026, 1:27 p.m. | Last Modified: 18 Aug 2026, 1:28 p.m.
Panel Version: 2.478
Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal
Phenotypes
Syndromic disease, MONDO: 0002254, IRS1-related
No evidence for Mendelian gene-disease association.Created: 16 Mar 2022, 8:27 p.m.
Phenotypes
{Coronary artery disease, susceptibility to}; {Type 2 diabetes mellitus, susceptibility to}, MIM# 125853
Gene: irs1 has been classified as Amber List (Moderate Evidence).
gene: IRS1 was added gene: IRS1 was added to Growth failure. Sources: Expert Review Amber,Victorian Clinical Genetics Services Mode of inheritance for gene: IRS1 was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: IRS1 were set to Syndromic disease, MONDO: 0002254, IRS1-related